This Liver Cancer Drug Keeps Failing for a Reason Nobody Expected
The FDA rejected Elevar and Hengrui's liver cancer combo for the third time, and it has nothing to do with whether the drug works. The culprit is a manufacturing facility in China that keeps failing inspection, threatening a billion-dollar deal while competitors cement their grip on the market.
Imagine acing every exam in medical school, only to be denied your degree because the printer jammed on your diploma. That's essentially what just happened to Elevar Therapeutics and Hengrui Pharma.
The FDA rejected their liver cancer combination therapy for the third time on manufacturing grounds. Not because the drug doesn't work. Not because patients had safety problems. Because the factory that makes one of the two drugs still can't pass inspection.
Three Strikes at the Plate
The combo in question pairs camrelizumab (a PD-1 checkpoint inhibitor made by Hengrui) with rivoceranib (a VEGF-targeting pill controlled by Elevar). Together, they're designed as a first-line treatment for patients with unresectable or metastatic hepatocellular carcinoma, the most common form of liver cancer.
The FDA communicates rejections through something called a Complete Response Letter (CRL), which is the regulatory equivalent of "we're not mad, we're disappointed." This combo has now collected CRLs like frequent flyer miles: one in May 2024, another in March 2025, and now a third in July 2026.
The first two pointed to Hengrui's camrelizumab manufacturing facility in Suzhou, China. The third cited deficiencies found during a cGMP inspection of a manufacturing site in China operated by Hengrui and named in the application.
The Clinical Data Is Actually Great
This is what makes the whole saga so maddening. The drug works.
In the pivotal Phase 3 CARES-310 trial, patients on the combo lived a median of 23.8 months, compared to 15.2 months on sorafenib (the old standard). That's roughly eight extra months of life, which in liver cancer is enormous. The combination cut the risk of death by about 36%.
Progression-free survival (the time before the cancer starts growing again) also improved significantly. The combo reduced the risk of disease progression by nearly half compared to sorafenib. Response rates were higher. Results held up across patient subgroups regardless of age, geography, or whether the cancer was caused by hepatitis.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The FDA has never questioned any of this. Elevar's leadership has repeatedly emphasized that the agency raised zero concerns about clinical data or rivoceranib's manufacturing. The entire problem sits inside one building in Suzhou.
What's Wrong With the Factory?
FDA inspectors first visited the facility in 2023 and came back with a 10-page list of problems (formally called a Form 483). The issues were serious: data integrity failures, inadequate contamination controls, and the risk of mixing up raw materials intended for the Chinese and American markets.
Think of it like a restaurant kitchen where inspectors found questionable record-keeping, spotty sanitation protocols, and ingredients for two different menus stored in the same unlabeled bins. You might make great food, but nobody's giving you a health certificate.
After the first CRL in May 2024, Elevar and Hengrui scrambled to fix the problems. They met with the FDA in July 2024, and the agency confirmed their corrective actions looked sufficient. The companies resubmitted their applications in September 2024, feeling optimistic.
Then came CRL number two in March 2025. FDA inspectors had returned in January 2025 and acknowledged that all original shortfalls were resolved. But they found three new issues. It was like fixing every pothole on a road only to have the inspector notice the guardrails are rusty.
The companies regrouped again, resubmitting in January 2026 with a new FDA decision date of July 23, 2026. They publicly stated the applications "fully address the previously raised concerns." Clearly, the FDA disagreed.
A Pattern Bigger Than One Drug
This isn't just an Elevar/Hengrui problem. It's part of a broader trend that should worry anyone betting on China-partnered drugs reaching the U.S. market.
An analysis of FDA Complete Response Letters from 2020 to 2024 found that 74% involved quality or manufacturing deficiencies. For biologics with overseas manufacturing, facility inspection problems have become an increasingly common reason for rejection. Toripalimab, another Chinese-developed cancer immunotherapy, faced similar delays when FDA couldn't inspect its manufacturing site during the pandemic.
The pattern is clear: the FDA isn't just evaluating whether a molecule works. It's scrutinizing where and how that molecule gets made. For companies relying on manufacturing partners thousands of miles from FDA headquarters, that scrutiny adds a layer of risk that no amount of clinical data can offset.
The Competitive Clock Is Ticking
While Elevar and Hengrui keep circling the runway, the first-line liver cancer market isn't standing still.
Two immunotherapy combos already dominate. Atezolizumab plus bevacizumab (Roche/Genentech) was the first checkpoint inhibitor combination approved for this setting, built on the landmark IMbrave150 trial. Tremelimumab plus durvalumab (AstraZeneca's STRIDE regimen) followed in 2022 and has carved out its own niche, especially for patients who can't tolerate anti-VEGF therapy. Both are listed as preferred first-line options in NCCN guidelines.
Every month of delay means these competitors dig deeper moats: more real-world data, more physician familiarity, more entrenched prescribing habits. Even if camrelizumab plus rivoceranib eventually reaches the U.S. market, it will be arriving late to a party where the guests already have their drinks.
What Happens Next
The financial stakes are significant. Elevar's commercialization deal with Hengrui includes up to $600 million in sales milestones and double-digit royalties, with an estimated total payout that could reach $1 billion over ten years. None of that materializes without U.S. approval.
HLB, Elevar's Korean parent company, has already seen its stock drop roughly 30% after earlier rejections. A third CRL transforms what was once perceived as a timing nuisance into something that looks like structural regulatory risk.
The companies will almost certainly request another meeting with the FDA to understand exactly what went wrong this time. If history is any guide, the average turnaround from a manufacturing-related CRL to resubmission runs six to seven months, though the range is wide.
But at some point, the market's patience runs out. The clinical data for this combo remains compelling; that was never in doubt. The question now is whether Hengrui can finally get its manufacturing house in order before the opportunity window closes for good.
A billion-dollar drug that can't get out of the factory is, ultimately, just an expensive science project.
Deals & M&A4 min read
Bayer Just Sold a Piece of Its Birth Control Empire (But Kept the Keys)
Bayer just pulled €3 billion from Apollo without giving up control of its blockbuster IUD franchise. It's a clever financial move, but the real story is why the German pharma giant needed the cash so badly in the first place.
